Success Metrics

Active Trials
7(88%)

Phase Distribution

Ph phase_1
8
100%

Phase Distribution

8

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
8(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

7

trials recruiting

Total Trials

8

all time

Status Distribution
Active(7)
Terminated(1)

Detailed Status

Active, not recruiting4
Recruiting3
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
7
Success Rate
N/A
Most Advanced
Phase 1

Trials by Phase

Phase 18 (100.0%)

Trials by Status

recruiting338%
withdrawn113%
active_not_recruiting450%

Recent Activity

7 active trials
Showing 5 of 8
active_not_recruitingphase_1

Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer

NCT05633979
active_not_recruitingphase_1

A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma

NCT05683171
recruitingphase_1

A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer

NCT06807632
active_not_recruitingphase_1

DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers

NCT04388852
recruitingphase_1

A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT07244341
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT05633979Phase 1

Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer

Active Not Recruiting
NCT05683171Phase 1

A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma

Active Not Recruiting
NCT06807632Phase 1

A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer

Recruiting
NCT04388852Phase 1

DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers

Active Not Recruiting
NCT07244341Phase 1

A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

Recruiting
NCT03930953Phase 1

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

Active Not Recruiting
NCT06294548Phase 1

A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC

Recruiting
NCT05879484Phase 1

Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS

Withdrawn

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8